

Global Companion Diagnostics Market – Drivers, Restraints, Opportunities, Trends, and Forecasts: 2018–2024

<https://marketpublishers.com/r/G332FB93F0FEN.html>

Date: February 2018

Pages: 97

Price: US\$ 2,750.00 (Single User License)

ID: G332FB93F0FEN

Abstracts

Global Companion Diagnostics Market – Drivers, Restraints, Opportunities, Trends, and Forecasts: 2018–2024

Overview: Companion diagnostics are molecular tests that provide essential information for the safety and effective use of the corresponding drug. These tests assist healthcare professionals to decide whether a specific treatment product benefits patient for curing disease, predict drug toxicities, off-target effects of treatment, and other adverse effects related to the drug. It is also used during clinical trials to guide treatment, which can improve therapy responses and treatment outcomes. Currently, there are over 20 approved or cleared companion diagnostic tests and most of the tests are for cancer treatments targeting mutation. According to the estimation of National Cancer Institute, in the US, around 1.6 million new cases of cancer were diagnosed and 595,690 people have died due to cancer in 2016. According to the Canadian Cancer Society, 202,400 new cases of cancer and nearly 78,000 deaths were recorded in 2016. While in Europe, 1.3 million people were diagnosed in 2015. Further, according to the study of World Health Organization, approximately 14 million new cancer cases were diagnosed and is expected to grow by about 70% over the next 2 decades. The trend of increasing incidence of cancer & infectious diseases is catching up even in developing countries due to increased adoption of the Western lifestyle, which is expected to fuel the growth of the companion diagnostics market in coming years.

The companion diagnostics market is booming due to increasing patient base for infectious diseases & cancer globally, high adoption of companion diagnostics, growing demand for companion diagnostics, and emerging applications of companion diagnostics. Low awareness & lack of professionals to conduct tests and unfavorable

reimbursement scenario in developed & developing countries are few of the factors hampering the market growth to an extent.

Market Analysis: The “Global Companion Diagnostics” market is estimated to witness a CAGR of 19.6% during the forecast period 2018–2024. The market is analyzed based on four segments – technology, applications, end-users, and regions.

Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). North America is set to be the leading region for the companion diagnostics market growth followed by Europe, Asia Pacific, and Rest of the World.

Technology Analysis: The global companion diagnostics market, by technology, is segmented into polymerase chain reaction, immunohistochemistry, in-situ hybridization, next-generation sequencing, and others. Polymerase chain reaction occupied the largest share in 2017, and next-generation sequencing is expected to grow at a high CAGR in the coming years.

Application Analysis: The global companion diagnostics market, by application, is segmented into cancer, infectious disease, and others. The cancer application is further segmented into colorectal cancer, breast cancer, lung cancer, melanoma, and others. In 2017, cancer application occupied a significant market share and is expected to be the same during the forecast period due to increasing incidence of cancer, changing lifestyle, and growing

For instance, in February 2017, Roche announced the launch of Elecsys AMH Plus immunoassay, the first companion diagnostic to be approved for use in fertility. The key market players are receiving product approvals that are helping them to increase the market share. For instance, in June 2017, the US FDA granted approval to Thermo Fisher Scientific for NGS-based test known as the OncoPrint Dx Target test, which instantaneously evaluates 23 genes clinically related to NSCLC.

Benefits: The report provides complete details about the usage and adoption rate of companion diagnostics products in various regions. With that, key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, government initiatives toward the test adoption in the upcoming years along with the details of commercial tests available in the market. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key

stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

Key Stakeholders:

Contents

1 INDUSTRY OUTLOOK

- 1.1 Industry overview
- 1.2 Total addressable market
- 1.3 Industry Trends

2 REPORT OUTLINE

- 2.1 Report Scope
- 2.2 Report Summary
- 2.3 Research Methodology
- 2.4 Report Assumptions

3 MARKET SNAPSHOT

- 3.1 Market Definition – Infoholic Research
- 3.2 Importance of Companion diagnostics
- 3.3 Segmented Addressable Market (SAM)
- 3.4 Trends of the companion diagnostics market
- 3.5 Related Markets
 - 3.5.1 Personalized medicine
 - 3.5.2 Genetic testing Market
 - 3.5.3 Point-Of-Care Diagnostics Market

4 MARKET OUTLOOK

- 4.1 Overview
- 4.2 Regulatory Scenario
- 4.3 Market segmentation
- 4.4 PEST Analysis
- 4.5 Porter 5(Five) Forces

5 MARKET CHARACTERISTICS

- 5.1 DRO – Global Companion Diagnostics Market Dynamics
 - 5.1.1 Drivers
 - 5.1.1.1 Growing incidence of cancer across the globe

5.1.1.2 Rising adoption of companion diagnostics tests

5.1.1.3 Growing demand of personalized medicine

5.1.2 Opportunities

5.1.2.1 Emerging applications of companion diagnostics

5.1.2.2 Growing demand for next-generation sequencing

5.1.3 Restraints

5.1.3.1 Uncertain reimbursement scenario in developed and developing countries

5.1.3.2 Lack of professionals to perform the test

6 TECHNOLOGY: MARKET SIZE AND ANALYSIS

6.1 Overview

6.2 Polymerase Chain Reaction

6.3 In Situ Hybridization

6.4 Immunohistochemistry

6.5 Next-Generation Sequencing

6.6 Others

7 APPLICATION: MARKET SIZE AND ANALYSIS

7.1 Overview

7.2 Cancer

7.2.1 Lung cancer

7.2.2 Breast cancer

7.2.3 Colorectal cancer

7.2.4 Melanoma

7.2.5 Others

7.3 Infectious disease

7.4 Others

8 END USERS: MARKET SIZE AND ANALYSIS

8.1 Overview

8.2 Pharma and biopharma companies

8.3 Reference Laboratories

8.4 Others

9 REGIONS: MARKET SIZE AND ANALYSIS

- 9.1 Overview
- 9.2 North America
 - 9.2.1 Overview
 - 9.2.2 US
 - 9.2.3 Canada
- 9.3 Europe
 - 9.3.1 Overview
 - 9.3.2 UK
 - 9.3.3 Germany
 - 9.3.4 France
 - 9.3.5 Spain
- 9.4 APAC
 - 9.4.1 Overview
 - 9.4.2 India
 - 9.4.3 China
- 9.5 Rest of the World

10 COMPETITIVE LANDSCAPE

- 10.1 Overview

11 VENDOR PROFILES

- 11.1 F.Hoffmann-La Roche Ltd
 - 11.1.1 Overview
 - 11.1.2 Business Unit
 - 11.1.3 Geographic Presence
 - 11.1.4 Business Focus
 - 11.1.5 SWOT Analysis
 - 11.1.6 Business Strategy
- 11.2 Qiagen N.V.
 - 11.2.1 Overview
 - 11.2.2 Geographic Presence
 - 11.2.3 Business Focus
 - 11.2.4 SWOT Analysis
 - 11.2.5 Business Strategies
- 11.3 Abbott Laboratories
 - 11.3.1 Overview
 - 11.3.2 Business Unit

- 11.3.3 Geographic Presence
- 11.3.4 Business Focus
- 11.3.5 SWOT Analysis
- 11.3.6 Business Strategy
- 11.4 Myriad Genetics Inc.
 - 11.4.1 Overview
 - 11.4.2 Business Unit
 - 11.4.3 Business Focus
 - 11.4.4 SWOT Analysis
 - 11.4.5 Business Strategy
- 11.5 Agilent Technologies Inc.
 - 11.5.1 Overview
 - 11.5.2 Business Units
 - 11.5.3 Geographic Presence
 - 11.5.4 Business Focus
 - 11.5.5 SWOT Analysis
 - 11.5.6 Business Strategies

12 COMPANIES TO WATCH FOR

- 12.1 BioMerieux S.A.
 - 12.1.1 Overview
 - 12.1.2 BioMerieux S.A.: Recent Developments
- 12.2 Danaher Corporation (Leica Microsystems AG)
 - 12.2.1 Overview
 - 12.2.2 Danaher Corporation: Recent Developments
- 12.3 Resonance Health Limited
 - 12.3.1 Overview
 - 12.3.2 Resonance Health Limited: Recent Developments
- 12.4 Thermo Fisher Scientific
 - 12.4.1 Overview
 - 12.4.2 Thermo Fisher Scientific: Recent Developments
- 12.5 Genomic Health, Inc.
 - 12.5.1 Overview
 - 12.5.2 Genomic Health: Recent Developments

13 ANNEXURE

- 13.1 Abbreviations

Tables

Table 1 REGULATORY SCENARIO

Table 2 GLOBAL COMPANION DIAGNOSTICS MARKET REVENUE BY REGIONS, 2017–2024 (\$MILLION)

Table 3 GLOBAL COMPANION DIAGNOSTICS MARKET BY VENDOR RANKING, 2017

Table 4 OTHER PROMINENT VENDORS OF COMPANION DIAGNOSTICS MARKET

Table 5 F. HOFFMANN-LA ROCHE: OFFERINGS

Table 6 F. HOFFMANN-LA ROCHE: RECENT DEVELOPMENTS

Table 7 QIAGEN N.V.: PRODUCT OFFERINGS

Table 8 QIAGEN N.V.: RECENT DEVELOPMENTS

Table 9 ABBOTT LABORATORIES: PRODUCT OFFERINGS

Table 10 ABBOTT LABORATORIES: RECENT DEVELOPMENTS

Table 11 MYRIAD GENETICS: PRODUCT DESCRIPTION

Table 12 MYRIAD GENETICS: RECENT DEVELOPMENTS

Table 13 AGILENT TECHNOLOGIES INC.: PRODUCT OFFERINGS

Table 14 AGILENT TECHNOLOGIES INC.: RECENT DEVELOPMENTS

Table 15 BIOMERIEUX S.A.: SNAPSHOT

Table 16 DANAHER CORPORATION: SNAPSHOT

Table 17 RESONANCE HEALTH LIMITED: SNAPSHOT

Table 18 THERMO FISHER SCIENTIFIC: SNAPSHOT

Table 19 GENOMIC HEALTH: SNAPSHOT

Charts

Chart 1 RESEARCH METHODOLOGY OF GLOBAL COMPANION DIAGNOSTICS MARKET

Chart 2 GLOBAL COMPANION DIAGNOSTICS MARKET REVENUE, 2017–2024 (\$MILLION)

Chart 3 PEST ANALYSIS OF GLOBAL COMPANION DIAGNOSTICS MARKET

Chart 4 PORTER 5 FORCES ON GLOBAL COMPANION DIAGNOSTICS MARKET

Chart 5 DRO – IMPACT ANALYSIS OF GLOBAL COMPANION DIAGNOSTICS MARKET

Chart 6 KEY STAKEHOLDERS

Chart 7 GLOBAL COMPANION DIAGNOSTICS MARKET BY TECHNOLOGY SEGMENTATION, 2017 (%)

Chart 8 GLOBAL COMPANION DIAGNOSTICS MARKET BY APPLICATION SEGMENTATION, 2017 (%)

Chart 9 GLOBAL COMPANION DIAGNOSTIC MARKET BY CANCER APPLICATION

SEGMENTATION, 2017 (%)

Chart 10 GLOBAL COMPANION DIAGNOSTICS MARKET BY END-USERS

SEGMENTATION, 2017 (%)

Chart 11 GLOBAL COMPANION DIAGNOSTICS MARKET BY GEOGRAPHICAL

SEGMENTATION, 2017 (%)

Chart 12 COMPANION DIAGNOSTICS MARKET REVENUE IN NORTH AMERICA,
2017–2024 (\$MILLION)

Chart 13 COMPANION DIAGNOSTICS MARKET REVENUE IN EUROPE, 2017–2024
(\$MILLION)

Chart 14 COMPANION DIAGNOSTICS REVENUE IN ASIA-PACIFIC, 2017–2024
(\$MILLION)

Chart 15 COMPANION DIAGNOSTICS MARKET REVENUE IN REST OF THE
WORLD, 2017–2024 (\$MILLION)

Chart 20 QIAGEN N.V.: OVERVIEW SNAPSHOT

Chart 21 QIAGEN N.V.: GEOGRAPHICAL PRESENCE

Chart 22 QIAGEN N.V.: SWOT ANALYSIS

Chart 23 ABBOTT LABORATORIES: OVERVIEW SNAPSHOT

Chart 24 ABBOTT LABORATORIES.: BUSINESS UNITS

Chart 25 ABBOTT LABORATORIES: GEOGRAPHIC PRESENCE

Chart 26 ABBOTT LABORATORIES.: SWOT ANALYSIS

Chart 27 MYRIAD GENETICS: OVERVIEW SNAPSHOT

Chart 28 MYRIAD GENETICS: BUSINESS UNITS

Chart 29 MYRIAD GENETICS: SWOT ANALYSIS

Chart 30 AGILENT TECHNOLOGIES INC.: OVERVIEW SNAPSHOT

Chart 31 AGILENT TECHNOLOGIES INC.: BUSINESS UNITS

Chart 32 AGILENT TECHNOLOGIES: GEOGRAPHICAL PRESENCE

Chart 33 AGILENT TECHNOLOGIES INC.: SWOT ANALYSIS

I would like to order

Product name: Global Companion Diagnostics Market – Drivers, Restraints, Opportunities, Trends, and Forecasts: 2018–2024

Product link: <https://marketpublishers.com/r/G332FB93F0FEN.html>

Price: US\$ 2,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G332FB93F0FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

